Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Adverse events, laboratory parameters, vital signs
Throughout study
No
Clinical Trials
Study Director
Hoffmann-La Roche
United States: Food and Drug Administration
NO22068
NCT00811993
January 2009
March 2013
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
Alexandria, Minnesota 56308 | |
Phoenix, Arizona 85012 | |
Fountain Valley, California 92708 | |
Austin, Texas 78705 | |
Omaha, Nebraska 68114 | |
Washington, District of Columbia |